Valcret Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-12-2024
- Paid Up Capital ₹ 1.00 M
as on 12-12-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -1.35%
(FY 2022)
- Profit 16.34%
(FY 2022)
- Ebitda 124.91%
(FY 2022)
- Net Worth 12.43%
(FY 2022)
- Total Assets -2.08%
(FY 2022)
About Valcret Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ganesh Kumar and Gobind Nayyar serve as directors at the Company.
- CIN/LLPIN
U51397CH2011PTC033103
- Company No.
033103
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Valcret Life Sciences Private Limited offer?
Valcret Life Sciences Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, PCD Pharma Franchise, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Muscle Relaxant, Nutraceuticals & Dietary Supplements, Mineral Supplement, Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Valcret Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Kumar  | Director | 19-Jun-2013 | Current |
| Gobind Nayyar | Director | 11-Jul-2011 | Current |
Financial Performance of Valcret Life Sciences.
Valcret Life Sciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.35% decrease. The company also saw a substantial improvement in profitability, with a 16.34% increase in profit. The company's net worth Soared by an impressive increase of 12.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Valcret Life Sciences?
In 2020, Valcret Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Valcret Life Sciences?
Unlock and access historical data on people associated with Valcret Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Valcret Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Valcret Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
